CLINICAL STUDY OF HAPA-B OYAMA, KAORU; SHIMIZU, RYUSAKU
CHEMOTHERAPY,
1985, Letnik:
33, Številka:
Supplement5
Journal Article
Odprti dostop
The authors report on the results of their clinical investigation of HAPA-B, a new semisynthetic aminoglycoside antibiotic, and following results were obtained. 1. HAPA-B exhibited a wide-spectrum ...growth inhibitory action against gram-positive and gram-negative bacilli, and its antibacterial activity was somewhat stronger than that of NTL, AMK and GM against K. pneumoniae and S. marcescens. 2. HAPA-B was injected intramuscularly in doses of 400 mg per day for respiratory tract infection (RTI) and urinary tract infection (UTI). The responses were good in 9 (64.3%) out of 14 patients with RTI and excellent in 1 and good in 2 out of 3 patients with UTI. 3. As a side effect, transient elevation of eosinophile in 1, BUN in 1, LDH in 2 and GOT, GPT, Al-p in 1 case.
CLINICAL STUDY OF SULTAMICILLIN OYAMA, KAORU; SHIMIZU, RYUSAKU
CHEMOTHERAPY,
1985, Letnik:
33, Številka:
Supplement2
Journal Article
Odprti dostop
The authors report on the results of their clinical investigation of SBTPC, an ester bond compound of β-lactamase inhibitor sulbactam (SBT) and ampicillin (ABPC). The antibacterial activity of SBPTC ...was compared to those of ABPC, cefazolin (CEZ) and cephalothin (CET) in a total of 168 clinically isolated strains of S. aureus, E. coli, K. pneumoniae, E. cloacae, S. marcescens, Proteussp. and P. aeruginosa. SBTPC exhibited greater antibacterial activity against S. aureus, S. faecalis, E. coli and Proteus sp. than ABPC. Clinical evaluation was carried out in 16 patients with respiratory tract infection (RTI) and one patient withurinary tract infection (UTI). Response was excellent and good in 11 cases out of 16 RTI and good in one case of UTI. As a side effect, rash observed in 2 cases but adverse reaction disappeared within one week following discontinuance of administration.
CLINICAL STUDY OF DL-8280 OYAMA, KAORU; SHIMIZU, RYUSAKU
CHEMOTHERAPY,
1984, Letnik:
32, Številka:
Supplement1
Journal Article
Odprti dostop
The antibacterial activity of DL-8280 was compared to that of norfloxacin (NFLX), pipemidic acid (PPA) and nalidixic acid (NA) in a total of 168 clinically isolated strains of S. aureus, S. faecalis, ...E. coil, K. pneumoniae, E. cloacae, S. marcescens, Proteus and P. aeruginosa. DL-8280 exhibited far greater antibacterial activity against S. aureus and S. faecalis than did NFLX, PPA and NA, on the other hand it was proved to be almost the same antibacterial activity as NFLX against gram-negative bacilli. DL-8280 was then administered to a total of 22 patient, among whom there were 15 cases of respiratory tract infections (RTI) and 7 cases of urinary tract infections (UTI). The results obtained were good in 10 (66.0%) out of 15 RTI cases, excellent and good in 6 (85.7%) out of 7 UTI cases. As an adverse reaction, leucopenia was observed in 1 case who, however, returned to normal within 7 days after discontinuation of administration.
The authors report on the results of their clinical investigations of SBT/CPZ, a β-lactamase inhibitor sulbactam (SBT) and cefoperazone (CPZ) in combination. The antibacterial activity of SBT/CPZ was ...compared to those of CPZ alone and SBT alone in a total of 178 clinically isolated strains of S. aureus, S. faecalis, E. coil, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus and P. aeruginosa. SBT/CPZ exhibited greater antibacterial activity against S. aureus, S. faecalis, E. coli, Serratia, Proteus and P. aeruginosa than CPZ alone, while no clear antibacterial activity of SBT was noticed against gram positive and negative bacteria. SBT/CPZ was then administered to a total of 18 patients, among whom there were 11 cases of respiratory tract infections (RTI), 1 case of septicemia and 6 cases of urinary tract infections (UTI). Results obtained were good in 9 (81.8%) out of 11 RTI cases, good in the sole case of septicemia and good in 5 (83.3%) out of 6 UTI cases. As adverse reactions and abnormal laboratory findings diarrhea were observed in 3 out of 18 patients and GPT elevated in 1. These adverse reactions, however, returned to normal after the completion of administration.
CLINICAL STUDY OF TA-058 OYAMA, KAORU; SHIMIZU, RYUSAKU
CHEMOTHERAPY,
1984, Letnik:
32, Številka:
Supplement2
Journal Article
Odprti dostop
The authors report on the results of their clinical investigations of TA-058, a new semisynthetic penicillin antibiotic. The antibacterial activity of TA-058 was compared to that of ampicillin (ABPC) ...and piperacillin (PIPC) in a total of 150 clinically isolated strains of S. aureus, E. coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Psudomanas and Proteus. TA-058 exhibited greater antibacterial activity against P. mirabilis than did ABPC and PIPC, and it was proved to be almost the same or slightly weak as PIPC against other strains. TA-058 was then administered to a total of 17 patients, among whom there were 13 cases of respiratory tract infections (R. T. I.), one case of septicemia and 3 cases of urinary tract infections (U. T. I.). Results obtained were good in 10 (77.0%) out of 13 R. T. I., good in the sole case of septicemia and U. T. I. also showed good in all cases. No side effect nor adverse reaction of the drug observed in all cases.
The authors report on the results of their clinical investigations of ceftriaxone (CTRX, Ro 13-9904) a newly developed semisynthetic cephalosporin with a long half life. The antibacterial activity of ...CTRX was compared to those of cefoperazone (CPZ), cefotaxime (CTX) and gentamicin (GM) in a total of 142 clinically isolated strains of E. coli, Citrobacter, Klebsiella, Enterobacter, S. marcescens, Proteus and P. aeruginosa. CTRX exhibited far greater antibacterial activity against E. coli, Klebsiella and P. mirabilis than did CPZ, CTX and GM. CTRX was then evaluated for efficacy and safety in 18 patients, among whom there were 17 cases of respiratory tract'infections (RTI) and 1 case of urinary tract infection (UTI). The results obtained were excellent and good in 13 cases (76.5%) out of 17 RTI, while good in sole case of UTI. No adverse reaction of drug was observed in this study.
The authors have carried out in-vitro and clinical evaluations of ceftazidime (CAZ, SN 401), a new semisynthetic cephalosporin antibiotic. The antibacterial activity of CAZ was compared to that of ...cefotaxime (CTX), cefmenoxime (CMX), cefoperazone (CPZ) and gentamicin (GM), against a total of 156 clinically isolated strains of S. aureus, E. coil, K. pneumoniae, Enterobacter, S. marsescens, Proteus, and P. aeruginosa. The antibacterial activity of CAZ against S. aureus, E. coil, K. pneumoniae, Enterobacter, S. marsescens and Proteus was comparable to those of CTX and CMX. Against P. aeruginosa, it was comparable to that of GM and more active than CTX, CMX and CPZ. CAZ was administered to a total of 17 patients: 16 with respiratory tract infections (RTI) and 1 with urinary tract infection (UTI). The clinical results obtained were excellent or good in 14 (87.5%) out of the 16 cases of RTI and good in the case of UTI. No side effect of the drug was observed.
The authors report on the results of their clinical investigation of cefpiramide (CPM, SM-1652), newly developed broad-spectrum cephem antibiotic. The antibacterial activity of cefpiramide was ...compared to that of cefazolin, cefotaxime and cefoperazone in a total of 178 clinical isolated strains of S. aureus, S. faecalis, E.coli, Citrobacter, Klebsiella, Enterobacter, Serratia, Proteus and P.aeruginosa. Cefpiramide was the most active against S. faecalis and almost the same antibacterial activity as cefotaxime and cefoperazonc against P.aeruginosa. On the contrary, cefpiramide was somewhat inferior to that of cefotaxime and cefoperazone against S. aureus, E.coli, Citrobacter, Klebsiella, Enterobacter and Proteus. The serum concentration and urinary excretion rate after 0.5g and 1g of cefpiramide drip infusion were examined in 2 patients with normal renal function. The serum concentration was detected up to 24 hours after injection and urinary excretion rate of cefpiramide was less than 30% by 24 hours. Clinical evaluation was carried out in 15 patients with respiratory tract infection (RTI) and 5 patients with urinary tract infection (UTI). Response was excellent and good in 12 (80%) out of 15 RTI cases and in 4 (80%) out of 5 UTI cases. As a side effect, rash was noticed in one case, eosinophilia observed in one case and slight elevation of GPT in one case, but adverse reaction returned to normal following the completion of administration.
CLINICAL STUDY ON T-1982 OHYAMA, KAORU; SHIMIZU, RYUSAKU
CHEMOTHERAPY,
1982/12/25, Letnik:
30, Številka:
Supplement3
Journal Article
Odprti dostop
The authors reported on the results of clinical investigations of T-1982, a new cephamycin antibiotic. 1) Antibacterial activity of T-1982 was compared to that of cefazolin (CEZ) and cefmetazole ...(CMZ) against clinically isolated gram-negative bacilli, and its antibacterial activity was superior to that of CEZ and CMZ against E. coli, Citrobacter, Klebsiella, Enterobacter, Serratia and Proteus. 2) T-1982 was administered by intravenous drip infusion to 20 patients with respiratory tract infection and 2 patients with urinary tract infection. Responses were excellent in 1 and good in 15 out of 20 respiratory tract infections and good in 2 of urinary tract infection. 3) As a side effect, slight grade of GOT and GPT elevation were observed in 2.
CLINICAL STUDY ON AM-715 OYAMA, KAORU; SHIMIZU, RYUSAKU
CHEMOTHERAPY,
1981/12/25, Letnik:
29, Številka:
Supplement4
Journal Article
Odprti dostop
The authors report the results of clinical investigations of AM-715, a new compound of quinolinecarboxylic acid. The antibacterial activity of AM-715 was compared with those of nalidixic acid (NA) ...and pipemidic acid (PPA) in a total of 178 clinically isolated strains of S. aureus, S. faecalis, E. coli, Citrobacter, K. pneumoniae, Enterobacter, S. marcescens, Proteus and P. aeruginosa. AM-715 exhibited far greater antibacterial activity against all of above strains, than did NA or PPA. AM-715 was then administered to a total of 23 patients, among whom there were 16 cases of respiratory tract infections (RTI), 7 cases of urinary tract infections (UTI). The results obtained were good in 10 (62.5%) out of 16 RTI cases, and excellent and good in 6 (85.7%) out of 7 UTI cases. As a side effect, one patient complained of nausea and anorexia, then it was necessary to discontinue the AM-715 administration, no additional adverse reaction was noted.
